CAR T-Cell Therapy: What It Is & How It Works

By: Dr. Mahesh Rajashekaraiah
Head & Chief Consultant Haematologist & Bone Marrow Transplant Physician
Posted on November 4, 2024

CAR T-Cell Therapy: What It Is & How It Works

CAR T-cell therapy is an advanced cancer immunotherapy that uses genetically modified T-cells to identify and destroy cancer cells more effectively. It is primarily used for relapsed or treatment-resistant blood cancers such as leukaemia, lymphoma, and multiple myeloma.

This guide explains how CAR T-cell therapy works, eligibility criteria, side effects, recovery, success rates, and why India is emerging as a leading destination for affordable, world-class CAR T-cell treatment.

Table of Contents

What is CAR T-Cell Therapy?

CAR T-cell therapy is an innovative immunotherapy that modifies a patient’s own T-cells to recognise and destroy cancer cells more effectively.

The process involves:

  • Collecting T-cells from the patient’s blood
  • Genetically engineering them with Chimeric Antigen Receptors (CARs)
  • Multiplying the modified cells
  • Infusing them back into the patient’s body

This targeted approach helps attack cancer cells while minimising damage to healthy tissues.

Who Qualifies for CAR T-Cell Therapy?

General Eligibility Criteria

  • Relapsed or refractory blood cancers
  • Failure of at least two prior treatment lines
  • Adequate organ function
  • Good performance status (ECOG 0–1)
  • Ability to tolerate the treatment timeline

Who May Not Be Eligible

  • Patients with uncontrolled infections
  • Severe cardiac, liver, lung, or kidney disease
  • Rapidly progressing disease
  • Patients on active immunosuppressive therapy

What Conditions Can CAR T-Cell Therapy Treat?

CAR T-cell therapy is mainly used for blood cancers.


Cancer Type Approval Status Target Antigen
B-cell ALL FDA Approved CD19
Diffuse Large B-cell Lymphoma (DLBCL) FDA Approved CD19
Mantle Cell Lymphoma FDA Approved CD19
Follicular Lymphoma FDA Approved CD19
Multiple Myeloma FDA Approved BCMA

How Does CAR T-Cell Therapy Work?

  1. T-cell Collection
    T-cells are collected through leukapheresis.
  2. Genetic Engineering
    The cells are modified to recognise cancer antigens.
  3. T-cell Expansion
    Millions of CAR T-cells are grown in a laboratory.
  4. Conditioning Chemotherapy
    Low-dose chemotherapy prepares the body.
  5. CAR T-cell Infusion
    Modified cells are infused through an IV line.
  6. Monitoring & Follow-Up
    Patients are closely monitored for response and side effects.

CAR T-Cell Therapy Treatment Timeline


Phase Timeline What Happens
Initial Evaluation Week 1–2 Assessment and eligibility confirmation
Leukapheresis Week 2–3 T-cell collection
Manufacturing Week 3–6 CAR T-cell engineering and expansion
Conditioning Chemotherapy Days -5 to -3 Preparation for infusion
CAR T-cell Infusion Day 0 Modified cells infused via IV
Acute Monitoring Day 1–14 CRS and neurotoxicity monitoring

What Happens Before, During & After CAR T-Cell Therapy?

Before Treatment

  • Medical evaluation
  • Blood tests and imaging
  • Leukapheresis procedure
  • Conditioning chemotherapy

During Treatment

  • CAR T-cell infusion via IV
  • Continuous monitoring in hospital
  • Supportive care management

After Treatment

  • Frequent follow-up visits
  • Monitoring for side effects
  • PET/CT scans and blood tests
  • Long-term remission surveillance

CAR T-Cell Therapy Recovery Timeline


Time Period Recovery Expectations
Week 1–2 Highest CRS and neurotoxicity risk
Week 2–4 Gradual improvement and discharge
Month 1–3 Immune recovery and first response assessment
Month 3–6 Return to light activities
Month 6–12 Near-normal energy and long-term follow-up

Side Effects of CAR T-Cell Therapy

  • Cytokine Release Syndrome (CRS)
  • Neurological toxicities
  • Infections
  • Anaemia and neutropenia
  • Tumour lysis syndrome
  • Fatigue and weakness

Cytokine Release Syndrome (CRS): Severity Grading


Grade Symptoms Treatment
Grade 1 Fever, fatigue, headache Supportive care
Grade 2 Low blood pressure, oxygen support IV fluids, tocilizumab
Grade 3 Severe hypotension and respiratory distress ICU care and steroids
Grade 4 Life-threatening multi-organ failure Aggressive ICU management

Benefits of CAR T-Cell Therapy

  • Highly targeted treatment approach
  • Personalised immunotherapy
  • Potential for durable remission
  • Reduced damage to healthy tissues
  • Improved quality of life

How Successful Is CAR T-Cell Therapy?

Success rates vary depending on cancer type, patient condition, and prior treatments.


Cancer Type Complete Remission Rate Overall Response Rate
B-cell ALL 70–90% 80–90%
DLBCL 40–54% 52–73%
Mantle Cell Lymphoma 67% 87%
Multiple Myeloma 33–39% 73–98%

CAR T-Cell Therapy vs Other Cancer Treatments

CAR T vs Chemotherapy

CAR T-cell therapy targets cancer-specific markers, while chemotherapy affects both cancerous and healthy rapidly dividing cells.

CAR T vs Bone Marrow Transplant

CAR T-cell therapy uses genetically modified T-cells and generally involves shorter recovery compared with bone marrow transplant.

CAR T vs Targeted Therapy

CAR T-cells may persist for years as living immune surveillance, while targeted therapy effects often stop once medication is discontinued.

CAR T-Cell Therapy Cost in India

India provides CAR T-cell therapy at significantly lower cost compared with the US and Europe while maintaining international clinical standards.

Request a Personalised Cost Estimate

Why International Patients Choose India for CAR T-Cell Therapy

  • 70–90% cost savings
  • Experienced haematology and BMT specialists
  • NABH-accredited hospitals
  • India-manufactured CAR T-cell products
  • Comprehensive international patient support
  • Minimal waiting times

When to See a Doctor

  • Relapsed or refractory cancer
  • Lack of response to chemotherapy
  • Aggressive blood cancers
  • Need for advanced immunotherapy options

Conclusion

CAR T-cell therapy represents one of the most advanced and promising cancer treatments available today. It offers new hope for patients with relapsed or treatment-resistant blood cancers through highly targeted immunotherapy.

SPARSH Hospitals – Global Care provides comprehensive CAR T-cell therapy support with experienced haematology specialists and dedicated international patient services.

Contact SPARSH Hospitals – Global Care

Phone / WhatsApp: +91 080 61 222 000
WhatsApp: +91 98442 61374